Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis

Wanlong Wu(Shanghai Jiao Tong University), Shuang Ye(Little Swan (China)), Danting Zhang(National Clinical Research Center for Digestive Diseases), Zhiwei Chen(Shanghai Jiao Tong University), Kaiwen Wang(Fudan University), Yakai Fu(Inserm), Li Guo(Shanghai Jiao Tong University), Wenwen Xu(Soochow University)
Clinical Reviews in Allergy & Immunology
January 6, 2021
10.1007/s12016-020-08822-5
Cited by 210

Related Papers

Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications
|Nature Communications|2022|112
Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram
|Patient Preference and Adherence|2018|111
CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease
|Lara D. Veeken|2018|60
Effectiveness and safety of tofacitinib<i>versus</i>calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study
|European Respiratory Journal|2025|48
A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis
|Scientific Reports|2021|35